^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Immune checkpoint inhibitor options in this setting include anti-PD-1 monotherapy with pembrolizumab (category 1) or nivolumab (category 1) or nivolumab/ipilimumab combination therapy (category 1). The NCCN Panel considers all recommended immune checkpoint inhibitor options appropriate for both BRAF mutant and BRAF wild-type metastatic disease.
